Advertisement

Topics

‘Removing the need for other partners’: Onyx invests in commercial API license

04:25 EDT 11 Jul 2019 | in-PharmaTechnologis

Onyx invests in a commercial API license and expands its UK facility to bolster its manufacturing capabilities for niche, small-scale production.

Original Article: ‘Removing the need for other partners’: Onyx invests in commercial API license

NEXT ARTICLE

More From BioPortfolio on "‘Removing the need for other partners’: Onyx invests in commercial API license"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...